A Phase 1/2a Study of the Efficacy and Safety of ASN-002 Alone or in Combination With 5-FU in Adult Patients With Low-risk Nodular Basal Cell Carcinoma

Trial Profile

A Phase 1/2a Study of the Efficacy and Safety of ASN-002 Alone or in Combination With 5-FU in Adult Patients With Low-risk Nodular Basal Cell Carcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Fluorouracil (Primary) ; TG 1042 (Primary)
  • Indications Basal cell cancer
  • Focus Adverse reactions
  • Sponsors Ascend Biopharmaceuticals
  • Most Recent Events

    • 23 Jan 2017 A combination of 5-FU has been used in the study due to which official title, purpose and treatment are changed hence protocol is amended.
    • 23 Jan 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Jan 2018.
    • 07 Nov 2016 According to Biopharmaceuticals media release, Rodney Sinclair is the principal investigator in this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top